TOVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Theriva Biologics Inc (TOVX) is not a good buy for a beginner, long-term investor at this time. The financial performance is weak, with significant declines in net income and EPS. There are no positive trading trends, no recent news or catalysts, and no strong technical signals to suggest a compelling entry point. Additionally, the pre-market price is down 3.05%, indicating negative sentiment.
The MACD is slightly positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 56.014, and moving averages are converging, indicating no clear trend. Key support is at 0.167, and resistance is at 0.24. The pre-market price of 0.191 is below the pivot level of 0.203, which is a bearish indicator.
NULL identified. No recent news, no significant insider or hedge fund activity, and no congress trading data.
Weak financial performance with a significant decline in net income (-43.55% YoY) and EPS (-93.39% YoY). Pre-market price is down 3.05%, and there are no significant trading trends or positive sentiment indicators.
In Q3 2025, the company's revenue remained at 0 with no growth. Net income dropped significantly to -$4,361,000 (-43.55% YoY), and EPS fell sharply to -0.45 (-93.39% YoY). Gross margin remains at 0 with no improvement.
No data available for analyst ratings or price target changes.
